Atypical antipsychotic (second generation)
Pregnancy: Use only if essential. Neonatal effects similar to other antipsychotics.
Quetiapine
Brand names: Seroquel, Atrolak, Brancico
Adult dose
Dose: Schizophrenia: 300–450 mg/day; Bipolar mania: 400–800 mg/day; Depression in bipolar: 50–300 mg/day at night
Route: Oral
Frequency: Twice daily (immediate-release); once daily (extended-release)
Max: 800 mg/day
Schizophrenia (IR): 25 mg BD day 1, 50 mg BD day 2, 100 mg BD day 3, titrate to 300–450 mg/day in divided doses. Bipolar mania: titrate to 400–800 mg/day. Extended-release: once daily, taken without food at night.
Paediatric dose
Route: Oral
Frequency: Twice daily
Max: 600 mg/day (adolescents)
13–17 years (schizophrenia): 25 mg BD day 1, 50 mg BD day 2, 100 mg BD day 3, titrate to 400–600 mg/day. Bipolar mania (10–17 years): 25 mg BD day 1, titrate to 400–600 mg/day.
Dose adjustments
Renal
No dose adjustment required.
Hepatic
Start at 25 mg and increase slowly in hepatic impairment.
Clinical pearls
- Quetiapine 25–50 mg used off-label for insomnia in many settings — generally discouraged (metabolic risk, no licence)
- Lens opacity screening: ophthalmology exam at baseline and every 2 years
- Titrate slowly in elderly (orthostatic hypotension and sedation risk)
- Metabolic monitoring mandatory: weight, glucose, lipids (same as olanzapine)
- Extended-release preferred for better patient adherence
Contraindications
- Hypersensitivity to quetiapine
- Concomitant CYP3A4 inhibitors (e.g., azole antifungals, macrolides — if at therapeutic dose)
Side effects
- Sedation (common — dose-dependent)
- Orthostatic hypotension
- Weight gain
- Metabolic syndrome (hyperglycaemia, dyslipidaemia)
- Dry mouth
- Constipation
- QT prolongation
- Cataracts (long-term — annual eye exams)
Interactions
- CYP3A4 inhibitors (ketoconazole, clarithromycin) — increase quetiapine levels 5–6×
- CYP3A4 inducers (carbamazepine, rifampicin) — reduce quetiapine levels
- CNS depressants — additive sedation
- Antihypertensives — enhanced hypotension
Monitoring
- Weight and BMI
- Fasting glucose and lipids
- BP
- ECG (QT)
- Ophthalmic exam (annual)
Reference: BNFc; BNF; NICE CG178; NICE NG185; Maudsley Prescribing Guidelines 14th ed.. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Duval/CIBMTR Score for AML in Second Complete Remission · Leukaemia
- R2-ISS — Second Revision International Staging System for Multiple Myeloma · Multiple Myeloma
- PANSS Brief — Positive and Negative Syndrome Scale (Abbreviated) · Psychosis Assessment
- Abnormal Involuntary Movement Scale (AIMS) · Movement Disorders
Pathways
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185 / BNF